Breaking News Instant updates and real-time market news.

2019-11-26 08:50:40 SPRO Spero Therapeutics $11.42 0.25 (2.24%) 08:50 11/26/19 11/26 08:50 11/26/19 08:50	Spero Therapeutics expects to report data from Phase 3 trial of SPR994 in 3Q20 Spero Therapeutics announced that it will host a key opinion leader breakfast symposium on the unmet need, treatment landscape and potential for oral SPR994 as a new therapeutic option in complicated urinary tract infections, as well as the opportunity for oral SPR720 in non-tuberculous mycobacterial infections. The event will be held on Thursday, December 5, 2019, from 8:30 a.m. - 10:30 a.m. ET in New York. As part of the event, Yoav Golan, MD, MS, FIDSA, Attending Physician and Associate Professor of Medicine at the Tufts University School of Medicine, will present an overview of the burden of disease in cUTI and the potential for oral SPR994 to change the treatment landscape. If approved, SPR994 has the potential to be the first oral carbapenem antibiotic for use in adults to treat cUTI. A pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI entitled ADAPT-PO continues to enroll patients, and Spero expects to report top-line data from the Phase 3 clinical trial in the third quarter of 2020. The Company will also present an overview of the progress in the SPR720 program. SPR720 is an orally administered antimicrobial agent being developed for the treatment of a rare, orphan disease, non-tuberculous mycobacterial infections and other infections, including Mycobacterium tuberculosis. SPR720 is currently being evaluated in a double-blind, placebo-controlled Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of SPR720 in healthy volunteers. Spero expects to report top-line data from the Phase 1 clinical trial by year-end 2019.
SPRO Spero Therapeutics $11.42 0.25 (2.24%) 09/09/19 JANY 09/09/19 INITIATION Target $27 JANY Buy Spero Therapeutics initiated with a Buy at Janney Montgomery Scott Janney Montgomery Scott initiated Spero Therapeutics with a Buy and $27 price target. 10/02/19 OPCO 10/02/19 NO CHANGE Target $20 OPCO Outperform Spero Therapeutics price target lowered to $20 from $30 at Oppenheimer Oppenheimer analyst Kevin DeGeeter lowered his price target for Spero Therapeutics to $20 from $30 based on removing SPR741 and SPR206 from his revenue model along with more modest commercial assumptions for SPR994. The analyst has an Outperform rating on the shares given potential for SPR994 to generate positive Phase III results and healthy commercial launch based on use as first-in-class oral carbapenem for nonhospital settings. 10/03/19 JANY 10/03/19 NO CHANGE Target $31 JANY Buy Spero price target raised to $31 from $27 at Janney Montgomery Scott Janney Montgomery Scott analyst Esther Hong raised her fair value estimate on shares of Spero Therapeutics to $31 from $27, citing her view that the company's Phase 3 study of SPR994 has been "meaningfully de-risked" by the lead-in pharmacokinetic data. Hong maintains a Buy rating on the stock. 11/05/19 HCWC 11/05/19 NO CHANGE Target $35 HCWC Buy Spero Therapeutics price target raised to $35 from $28 at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Spero Therapeutics to $35 from $28 after the company announced that an independent review committee evaluated pharmacokinetic data following enrollment of the first 70 patients and recommended that Spero continue the trial using the protocoldefined dose without modification. As a result, the analyst increased his SPR994 probability of launch to 85% from the previous 70%. He keeps a Buy rating on Spero Therapeutics.

2019-11-26 08:50:40

SPRO

Spero Therapeutics

$11.42: 0.25 (2.24%)

08:50

11/26/19

11/26

08:50

11/26/19

08:50

Spero Therapeutics expects to report data from Phase 3 trial of SPR994 in 3Q20

Spero Therapeutics announced that it will host a key opinion leader breakfast symposium on the unmet need, treatment landscape and potential for oral SPR994 as a new therapeutic option in complicated urinary tract infections, as well as the opportunity for oral SPR720 in non-tuberculous mycobacterial infections. The event will be held on Thursday, December 5, 2019, from 8:30 a.m. - 10:30 a.m. ET in New York. As part of the event, Yoav Golan, MD, MS, FIDSA, Attending Physician and Associate Professor of Medicine at the Tufts University School of Medicine, will present an overview of the burden of disease in cUTI and the potential for oral SPR994 to change the treatment landscape. If approved, SPR994 has the potential to be the first oral carbapenem antibiotic for use in adults to treat cUTI. A pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI entitled ADAPT-PO continues to enroll patients, and Spero expects to report top-line data from the Phase 3 clinical trial in the third quarter of 2020. The Company will also present an overview of the progress in the SPR720 program. SPR720 is an orally administered antimicrobial agent being developed for the treatment of a rare, orphan disease, non-tuberculous mycobacterial infections and other infections, including Mycobacterium tuberculosis. SPR720 is currently being evaluated in a double-blind, placebo-controlled Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of SPR720 in healthy volunteers. Spero expects to report top-line data from the Phase 1 clinical trial by year-end 2019.

SPRO Spero Therapeutics

$11.42: 0.25 (2.24%)

09/09/19: JANY

10/02/19: OPCO

10/03/19: JANY

11/05/19: HCWC

TODAY'S FREE FLY STORIES

WFT Weatherford $0.00 (0.00%) 18:49 12/13/19 12/13 18:49 12/13/19 18:49 Hot Stocks	Weatherford completes financial restructuring, emerges from Chapter 11 » Weatherford announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
CNC Centene $57.71 -0.81 (-1.38%) 18:40 12/13/19 12/13 18:40 12/13/19 18:40 Hot Stocks	Centene CEO: Our big markets are growing, we're gaining share » In an interview on… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	13 Dec
LYV Live Nation $64.24 -5.205 (-7.50%) , ZBRA Zebra Technologies $257.82 -0.32 (-0.12%) … 18:29 12/13/19 12/13 18:29 12/13/19 18:29 Hot Stocks	S&P announces changes to S&P 400, 500, 600 indices » S&P Dow Jones Indices… LYV Live Nation $64.24 -5.205 (-7.50%) ZBRA Zebra Technologies $257.82 -0.32 (-0.12%) STE Steris $151.93 -1.745 (-1.14%) AMG Affiliated Managers $85.18 -1.77 (-2.04%) TRIP TripAdvisor $29.24 -0.2 (-0.68%) MAC Macerich $26.04 -0.46 (-1.74%) LOPE Grand Canyon $89.24 -0.86 (-0.95%) LEA Lear $129.43 -0.84 (-0.64%) OAS Oasis Petroleum $2.68 -0.295 (-9.93%) SWN Southwestern Energy $2.00 -0.12 (-5.66%) UNT Unit Corp. $0.83 -0.0626 (-6.98%) FTR Frontier Communications $0.68 0.0315 (4.84%) ARWR Arrowhead $66.47 -0.91 (-1.35%) GVA Granite Construction $26.21 -1.335 (-4.85%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	26 Feb 23 Mar
PLAN Anaplan $51.80 1.44 (2.86%) 18:23 12/13/19 12/13 18:23 12/13/19 18:23 Hot Stocks	Anaplan CEO: Digitization has really started to accelerate » In an interview on… In an interview on CNBC's Mad Money, Anaplan CEO Frank Calderoni said: We've had four quarters since the IPO where we've been able to grow the top and bottom lines... Digitization has really started to accelerate and it's driving our results... We're increasing the number of new customers and current customers are spending more with us... The new world is all about real-time planning.. Over the next five years there's going to be a dramatic shift in planning. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
WPX WPX Energy $10.92 -0.24 (-2.15%) 18:08 12/13/19 12/13 18:08 12/13/19 18:08 Periodicals	WPX Energy in talks to acquire Felix Energy assets for $2.5B, Bloomberg says » WPX Energy is in… WPX Energy is in discussions to purchase the oil and gas exploration assets of Felix Energy for roughly $2.5B, Bloomberg's Kiel Porter and David Wethe report, citing people familiar with the matter. WPX could announce a deal with Felix later in December, though no final decision has been made and discussions could fall apart, the authors say. Felix Energy is backed by private equity firm EnCap Investments, and the deal currently in talks won't include Felix's pipeline assets, which are being sold separately, the authors note. Reference Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 Mar

HLIT Harmonic $7.94 -0.25 (-3.05%) 17:47 12/13/19 12/13 17:47 12/13/19 17:47 Hot Stocks	Harmonic CFO sells 28K shares of common stock » In a regulatory filing,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
HZNP Horizon Pharma $32.84 (0.00%) 17:36 12/13/19 12/13 17:36 12/13/19 17:36 Hot Stocks	Breaking Hot Stocks news story on Horizon Pharma » Horizon Pharma up 9.6% to… Horizon Pharma up 9.6% to $36.00 after FDA unit supports use of teprotumumab 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	13 Dec 08 Mar
AMRN Amarin $24.12 1.12 (4.87%) 17:33 12/13/19 12/13 17:33 12/13/19 17:33 Hot Stocks	Breaking Hot Stocks news story on Amarin » Amarin rises 1.4% to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Dec
THMO ThermoGenesis $2.88 (0.00%) 17:31 12/13/19 12/13 17:31 12/13/19 17:31 Syndicate	Breaking Syndicate news story on ThermoGenesis » ThermoGenesis files $30M… ThermoGenesis files $30M mixed securities shelf 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMRN Amarin $24.12 1.12 (4.87%) 17:30 12/13/19 12/13 17:30 12/13/19 17:30 Hot Stocks	Breaking Hot Stocks news story on Amarin Amarin trading resumes 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Dec

QTNT Quotient $8.60 -0.165 (-1.88%) 17:28 12/13/19 12/13 17:28 12/13/19 17:28 Syndicate	Breaking Syndicate news story on Quotient » Quotient files to sell… Quotient files to sell 105K ordinary shares for holders 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
ARWR Arrowhead $66.47 -0.91 (-1.35%) , GVA Granite Construction $26.21 -1.335 (-4.85%) 17:27 12/13/19 12/13 17:27 12/13/19 17:27 Hot Stocks	Breaking Hot Stocks news story on Arrowhead, Granite Construction » Arrowhead to replace… ARWR Arrowhead $66.47 -0.91 (-1.35%) GVA Granite Construction $26.21 -1.335 (-4.85%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
OAS Oasis Petroleum $2.68 -0.295 (-9.93%) , SWN Southwestern Energy $2.00 -0.12 (-5.66%) … 17:25 12/13/19 12/13 17:25 12/13/19 17:25 Hot Stocks	Oasis, Southwestern to replace Unit Corp., Frontier in S&P 600 at open on 12/23 » Oasis Petroleum (OAS) and… Oasis Petroleum (OAS) and Southwestern Energy (SWN) will replace Unit Corp. (UNT) and Frontier Communications (FTR) in the S&P SmallCap 600. OAS Oasis Petroleum $2.68 -0.295 (-9.93%) SWN Southwestern Energy $2.00 -0.12 (-5.66%) UNT Unit Corp. $0.83 -0.0626 (-6.98%) FTR Frontier Communications $0.68 0.0315 (4.84%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 Mar
AMRN Amarin $24.12 1.12 (4.87%) 17:24 12/13/19 12/13 17:24 12/13/19 17:24 Hot Stocks	Amarin raises guidance after FDA approves Vascepa » Amarin (AMRN) shares… Amarin (AMRN) shares rallied almost 5% in intraday trading on Friday before they were halted, news pending. After the market closed, the FDA announced it approved the use of Vascepa as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels of 150 milligrams per deciliter or higher. The statement added that Vascepa was the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy. Shortly afterward, Amarin confirmed the FDA announcement, raised its FY19 revenue guidance, and gave FY20 revenue guidance. The company raised its FY19 revenue view to $410M-$425M from $380M-$420M, against a consensus of $410.25M, and gave FY20 revenue guidance of $650M-$700M, against a consensus of $654.55M. The company said, "Amarin is providing this projected revenue guidance for 2020 and has based its projection on a number of factors, including, but not limited to, expectations on market acceptance of the newly expanded label for Vascepa and current plans for expanded promotion. Vascepa revenues are anticipated to continue to increase in 2020, accompanied by quarterly industry variability, including recurring seasonal factors, particularly in the first quarter... Beyond 2020, Amarin believes that Vascepa total net revenue will grow to reach multiple billions of dollars. " 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Dec
LOPE Grand Canyon $89.24 -0.86 (-0.95%) , LEA Lear $129.43 -0.84 (-0.64%) … 17:22 12/13/19 12/13 17:22 12/13/19 17:22 Hot Stocks	Grand Canyon, Lear to replace Oasis, Southwestern in S&P 400 at open on 12/23 » Grand Canyon Education… Grand Canyon Education (LOPE), and Lear (LEA) will replace Oasis Petroleum (OAS) and Southwestern Energy (SWN) in the S&P MidCap 400, respectively. LOPE Grand Canyon $89.24 -0.86 (-0.95%) LEA Lear $129.43 -0.84 (-0.64%) OAS Oasis Petroleum $2.68 -0.295 (-9.93%) SWN Southwestern Energy $2.00 -0.12 (-5.66%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	23 Mar

RTN Raytheon $217.31 -0.93 (-0.43%) 17:20 12/13/19 12/13 17:20 12/13/19 17:20 Hot Stocks	Raytheon awarded $123.53M Navy contract modification » Raytheon was awarded a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
LYV Live Nation $64.24 -5.205 (-7.50%) , ZBRA Zebra Technologies $257.82 -0.32 (-0.12%) … 17:19 12/13/19 12/13 17:19 12/13/19 17:19 Hot Stocks	Live Nation, Zebra Technologies, Steris to move to S&P 500 at open on 12/23 » Live Nation (LYV), Zebra… Live Nation (LYV), Zebra Technologies (ZBRA), and Steris (STE) will move to the S&P 500, switching places with Affiliated Managers Group (AMG), TripAdvisor (TRIP), and The Macerich Co (MAC) respectively. All companies moving to the S&P 500 have market capitalizations above $12B. LYV Live Nation $64.24 -5.205 (-7.50%) ZBRA Zebra Technologies $257.82 -0.32 (-0.12%) STE Steris $151.93 -1.745 (-1.14%) AMG Affiliated Managers $85.18 -1.77 (-2.04%) TRIP TripAdvisor $29.24 -0.2 (-0.68%) MAC Macerich $26.04 -0.46 (-1.74%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	26 Feb
BAESY BAE Systems $0.00 (0.00%) 17:15 12/13/19 12/13 17:15 12/13/19 17:15 Hot Stocks	BAE Systems awarded $249.15M Army contract modification » BAE Systems was awarded a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
WST West Pharmaceutical $146.32 -0.14 (-0.10%) 17:02 12/13/19 12/13 17:02 12/13/19 17:02 Hot Stocks	West Pharmaceutical announces 848K share repurchase authorization » On December 10, 2019, the… On December 10, 2019, the company's board authorized a share repurchase program for calendar-year 2020 authorizing the repurchase of up to 848,000 shares of the company's common stock from time to time on the open market or in privately-negotiated transactions. The share repurchase program is expected to be completed by December 31, 2020. The company's previously-authorized share repurchase program will expire on December 31, 2019. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMRN Amarin $24.12 1.12 (4.87%) 17:02 12/13/19 12/13 17:02 12/13/19 17:02 Earnings	Amarin sees FY20 revenue $650M-$700M, consensus $654.55M » With respect to 2020,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Dec

IBIO iBio $0.22 -0.0179 (-7.43%) 17:01 12/13/19 12/13 17:01 12/13/19 17:01 Hot Stocks	iBio receives NYSE noncompliance notice » iBio, Inc. announced that… iBio, Inc. announced that on December 9, 2019, the company received a letter from NYSE American LLC indicating the company's securities have been selling for a low price per share for a substantial period of time and pursuant to Section 1003fv of the NYSE American Company Guide, the company's continued listing on the Exchange is predicated on the company effecting a reverse stock split or otherwise demonstrating sustained improvement in its share price within a reasonable period of time, which the Exchange has determined to be no later than June 9, 2020. Additionally, the company does not currently meet certain other NYSE American continued listing standards as set forth in Part 10, Section 1003(a)(i), (ii) and (iii) of the Company Guide, due to the fact the company had reported stockholders' equity of less than $6.0M, as of September 30, 2019, and net losses in its five most recent fiscal years. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
APLT Applied Therapeutics $21.23 0.29 (1.38%) 16:59 12/13/19 12/13 16:59 12/13/19 16:59 Syndicate	Breaking Syndicate news story on Applied Therapeutics » Applied Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMRN Amarin $24.12 1.12 (4.87%) 16:59 12/13/19 12/13 16:59 12/13/19 16:59 Earnings	Amarin raises FY19 revenue view to $410M-$425M from $380M-$420M FY19 consensus $410.25M. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Dec
BIO Bio-Rad $354.69 -8.005 (-2.21%) 16:56 12/13/19 12/13 16:56 12/13/19 16:56 Hot Stocks	Bio-Rad progressing from ransomware attack recovery detected on Dec 5th » Bio-Rad Laboratories… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AMRN Amarin $24.12 1.12 (4.87%) 16:50 12/13/19 12/13 16:50 12/13/19 16:50 Hot Stocks	Amarin confirms FDA approval of Vascepa » Amarin announced that the… Amarin announced that the FDA has approved a new indication and label expansion for Vascepa capsules. After more than a decade of development and testing, Vascepa is now the first and only drug approved by the FDA "as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease." It is estimated that millions of high-risk patients in the United States could benefit from this one-of-a-kind prescription therapy. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	28 Dec

Events

Earnings calls, analyst events, roadshows and more

Tomorrow at 00:00

San Antonio Breast Cancer Symposium 2019 Conferences

Henry B. Gonzalez Convention Center, San Antonio, TX
Tomorrow at 00:00

Marijuana Business Conference: MJBiz Conferences

Las Vegas Convention Center, Las Vegas, NV
Tomorrow at 00:00

ESMO Immuno-Oncology Congress 2019 Conferences

Geneva
Tomorrow at 00:00

8th Annual ROTH Deer Valley Conference Conferences

Deer Valley, UT
AMPE
Tomorrow at 11:00

Ampio Pharmaceuticals, Inc. Firm Sponsored Meetings

200 Inverness, Englewood, CO
AVDL
2019-12-15 at 00:00

PDUFA Date for AV001 Government Event
2019-12-15 at 00:00

8th Annual ROTH Deer Valley Conference Conferences

Deer Valley, UT
2019-12-16 at 00:00

Greater China Tourism/Consumer Tour Conferences

Taipei, Beijing
OKTA ...
2019-12-16 at 00:00

17th Semi-Annual Silicon Valley Technology Bus Tour Conferences

Silicon Valley, CA
TMUS
2019-12-16 at 00:00

T-Mobile Firm Sponsored Meetings

New York, NY

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	CRWD X CRWD Crowdstrike Block Trade Managers: Goldman Sachs Priced at: $49.40 2.2M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AUPH X AUPH Aurinia Pharmaceuticals Secondary Managers: Jefferies & SVB Leerink, H.C. Wainwright, Oppenheimer, Bloom Burton Priced at: $15.00 11.1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial XAIR X XAIR Beyond Air Secondary Managers: SunTrust, National Securities, Roth Capital, Laidlaw Priced at: $3.66 2.325M Shares ABR X ABR Arbor Realty Spot Secondary Managers: JPMorgan, JMP Securities & Raymond James Priced at: $14.14 6.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CFRX X CFRX ContraFect Spot Secondary Managers: Maxim Priced at: $.27 37.15M Shares RHP X RHP Ryman Hospitality Spot Secondary Managers: BofA/Merrill, JPMorgan & Wells Fargo Priced at: $85.60 3M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SCYX X SCYX Scynexis Spot Secondary Managers: H.C. Wainwright Priced at: $.90 38.89M Shares
Tues	XP X XP XP IPO Managers: Goldman Sachs, JPMorgan, Morgan Stanley, XP & Itau BBA, BofA/Merrill, Citi, Credit Suisse, UBS Priced at: $27.00 72.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CNST X CNST Constellation Pharmaceuticals Spot Secondary Managers: JPMorgan, Jefferies & Cowen, RBC Capital, SunTrust Priced at: $34.50 6.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GMRE X GMRE Global Medical REIT Spot Secondary Managers: Stifel, BMO Capital, Baird, KeyBanc & SunTrust Priced at: $13.00 6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Jaffray & Stifel, BTIG, JMP Securities, SunTrust Priced at: $36.50 1.57M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDGL X MDGL Madrigal Pharmaceuticals Spot Secondary Managers: Goldman Sachs Priced at: $107.85 1.2M Shares MRNS X MRNS Marinus Pharmaceuticals Spot Secondary Managers: Oppenheimer & Ladenburg Priced at: $1.25 28M Shares PACK X PACK Ranpak Holdings Spot Secondary Managers: Craig-Hallum Priced at: $6.50 15.384M Shares PMT X PMT PennyMac Mortgage Spot Secondary Managers: Morgan Stanley, Credit Suisse, BofA/Merrill, JPMorgan & Barclays, Nomura Instinet, Piper Jaffray Priced at: $22.10 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCKT X RCKT Rocket Pharmaceuticals Spot Secondary Managers: JPMorgan, Cowen & Evercore ISI, LifeSci Priced at: $22.25 3.82M Shares
Wed	BILL X BILL Bill.com IPO Managers: Goldman Sachs, BofA/Merrill, Jefferies & KeyBanc, Canaccord, Needham, William Blair Priced at: $22.00 9.824M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EH X EH Ehang IPO Managers: Morgan Stanley, Needham, Tigress Financial, Prime Number Priced at: $12.50 3.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LVGO X LVGO Livongo Health Secondary Managers: Morgan Stanley, Goldman Sachs & JPMorgan Priced at: $27.00 2.78M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MNRL X MNRL Brigham Minerals Secondary Managers: Credit Suisse, Goldman Sachs & RBC Capital Priced at: $18.10 11M Shares MNTA X MNTA Momenta Secondary Managers: Goldman Sachs & JPMorgan, Stifel Priced at: $15.50 14.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AKTS X AKTS Akoustis Spot Secondary Managers: Craig-Hallum, Roth Capital, Loop Capital Priced at: $6.25 4.8M Shares ASMB X ASMB Assembly Biosciences Spot Secondary Managers: Jefferies & SVB Leerink Priced at: $16.50 5.152M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FTSV X FTSV Forty Seven Spot Secondary Managers: Morgan Stanley & Credit Suisse Priced at: $35.00 4.86M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	LULU X LULU Lululemon Block Trade Managers: Morgan Stanley Priced at: $220.00 2.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HCCO X HCCO Healthcare Merger Corp. IPO Managers: Cantor Fitzgerald Priced at: $10.00 22M Shares OCFT X OCFT OneConnect IPO Managers: Morgan Stanley, Goldman Sachs, JPMorgan & Ping An of China, BofA/Merrill, HSBC, CLSA, KeyBanc Priced at: $10.00 31.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SPT X SPT Sprout Social IPO Managers: Goldman Sachs, Morgan Stanley, KeyBanc & William Blair, Canaccord, Stifel Priced at: $17.00 8.824M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AEMD X AEMD Aethlon Medical Secondary Managers: H.C. Wainwright Priced at: $1.50 3.333M Shares AQST X AQST Aquestive Therapeutics Secondary Managers: BMO Capital Priced at: $5.00 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PHR X PHR Phreesia Secondary Managers: JPMorgan, Wells Fargo, William Blair, Allen & Co., Piper Jaffray, Baird, Raymond James Priced at: $26.00 6.75M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial UTI X UTI Universal Technical Spot Secondary Managers: B. Riley FBR Priced at: $6.25 3.6M Shares
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	ASPU X ASPU Aspen Group Spot Secondary Managers: Canaccord $7.55 Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

Spero Therapeutics expects to report data from Phase 3 trial of SPR994 in 3Q20

TODAY'S FREE FLY STORIES

Get Full Fly Access